Aptevo Therapeutics Inc.

APVO • Biotechnology

$1.74

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$2.08M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.27Healthy liquidity · 3.82Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 19, 2026, 12:20 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.74

Change0.00%

Shares Out1.20M

Market Cap$2.08M

Enterprise Value$-3.51M

52W Range2.68 - 48.78

Beta1.65

P/E-0.08

P/B0.34

P/FCF-0.08

EV/EBITDA0.13

EV/FCF0.14

Price$1.74

Change0.00%

Shares Out1.20M

Market Cap$2.08M

Enterprise Value$-3.51M

52W Range2.68 - 48.78

Beta1.65

P/E-0.08

P/B0.34

P/FCF-0.08

EV/EBITDA0.13

EV/FCF0.14

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.27

Current Ratio3.82

Quick Ratio3.82

Volume47.04K

Avg Volume47.30K

EPS Surprise-0.81

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Manageable debt level · 0.27Healthy liquidity · 3.82Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

APVO

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 7/20/2016

Industry: Biotechnology

P/B i: 0.34

Debt / Equity i: 0.27

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.27

Current Ratio: 3.82

Quick Ratio: 3.82

Status: Good

Insider Transactions

Recent executive and insider activity

Niederhuber John

Transaction: 08/06/2026

SELL

Change

-400

Price

Not reported

Filing

08/10/2026

Type

SELL

Niederhuber John

Transaction: 08/06/2026

BUY

Change

+400

Price

$0.00

Filing

08/10/2026

Type

BUY

Kunz Barbara Lopez

Transaction: 08/06/2026

SELL

Change

-400

Price

Not reported

Filing

08/10/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Niederhuber John	SELL	-400	Not reported	08/06/2026	08/10/2026
Niederhuber John	BUY	+400	$0.00	08/06/2026	08/10/2026
Kunz Barbara Lopez	SELL	-400	Not reported	08/06/2026	08/10/2026
Kunz Barbara Lopez	BUY	+400	$0.00	08/06/2026	08/10/2026
Abdun-Nabi Daniel	SELL	-400	Not reported	08/06/2026	08/10/2026
Abdun-Nabi Daniel	BUY	+400	$0.00	08/06/2026	08/10/2026
White Marvin L	SELL	-1,666	Not reported	08/06/2026	08/10/2026
White Marvin L	SELL	-406	$4.07	08/06/2026	08/10/2026
Grant Grady III	SELL	-400	Not reported	08/06/2026	08/10/2026
Grant Grady III	BUY	+400	$0.00	08/06/2026	08/10/2026
Huebner Dirk	SELL	-638	Not reported	08/06/2026	08/10/2026
Huebner Dirk	SELL	-156	$4.07	08/06/2026	08/10/2026
Kwon SoYoung	SELL	-638	Not reported	08/06/2026	08/10/2026
Kwon SoYoung	BUY	+638	$0.00	08/06/2026	08/10/2026
Taylor Daphne	SELL	-638	Not reported	08/06/2026	08/10/2026
Taylor Daphne	BUY	+638	$0.00	08/06/2026	08/10/2026
Lamothe Jeffrey G.	SELL	-961	Not reported	08/06/2026	08/10/2026
Lamothe Jeffrey G.	BUY	+961	$0.00	08/06/2026	08/10/2026
Harsanyi Zsolt	SELL	-400	Not reported	08/06/2026	08/10/2026
Harsanyi Zsolt	BUY	+400	$0.00	08/06/2026	08/10/2026

About the Company

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

Source - link

Peers

ABP BCDA CERO EPIX ERNA HCWB INAB KPRX MTNB RADX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia patients carrying TP53 mutations.

Benzinga

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically responded poorly to treatment. "TP53-mutated AML remains one of the most challenging AML subpopulations to treat," said Dirk Huebner, M.D.

Accesswire

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity SEATTLE, WA / ACCESS Newswire / August 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2026 and provided a business update highlighting strong clinical progress for mipletamig, strengthened scientific leadership, non-dilutive funding to advance its solid tumor trispecific pipeline and expansion into radiopharmaceutical therapeutic development through a 50/50 collaboration with Niowave. "During the second quarter, we made important progress against the programs and initiatives we believe can create near- and long-term value for Aptevo," said Jeff Lamothe, President and Chief Executive Officer of Aptevo.

Accesswire

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company has issued new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share.

Accesswire

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share.

Accesswire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-13	-5.6	-6.41	-0.81
2026-03-20	-8.09	1684.47	1692.56
2025-11-06	-37.59	-40.11	-2.52
2025-08-11	-0.45	-151.08	-150.63
2025-05-15	-1514.39	-1579.14	-64.75
2025-03-04	-7.75	-82.37	-74.62
2024-11-07	-7428.84	-6255.86	1172.98
2024-08-08	-25153.79	-21765.2	3388.59
2024-05-08	-183766.03	-129678.87	54087.16
2024-03-05	-18.04	-6.16	11.88
2023-11-14	-413383.16	-287071.63	126311.53
2023-08-10	-643040.44	-706196.19	-63155.75